User menu

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.

Bibliographic reference Bousser, M G ; Amarenco, P ; Chamorro, A ; Fisher, M ; Ford, I ; et. al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.. In: Cerebrovascular Diseases, Vol. 27, no.5, p. 509-18 (2009)
Permanent URL http://hdl.handle.net/2078.1/132703